By Marina Zhang Some patients have been self-administering incorrect doses of semaglutide, the active ingredient in Wegovy and Ozempic, two popular weight-loss and Type 2 diabetes drugs, the U.S. Food and Drug Administration (FDA) states in an alert on Friday. As a result, some patients took five to 20 times the prescribed dose, with several requiring medical attention or hospitalization.
Source